{"url_path":"/sec/kphmw/8-k/2026-05-08/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1372514/0001372514-26-000048-index.html","accession_number":"0001372514-26-000048","cik":"0001372514","ticker":"KPHMW","issuer_name":"KIORA PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1372514/0001372514-26-000048-index.html","primary_entity_key":"0001372514","primary_entity_name":"KIORA PHARMACEUTICALS INC"},"word_count":122,"has_tables":true,"body_markdown":"Item 9.01.    Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit \nNumberTitle\n\n[99.1](ex991-pressreleasemarch312.htm)\n\n[Press Release of Kiora Pharmaceuticals, Inc., dated as of March 31, 2026](ex991-pressreleasemarch312.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document).\n\n*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nKIORA PHARMACEUTICALS, INC.\n\nBy:/s/ Melissa Tosca\n\nMelissa Tosca\n\nChief Financial Officer\n\n(Principal financial and accounting officer)\n\nDate: May 8, 2026"}